CellChorus to give two presentations at ISCT North America

International Society for Cell & Gene Therapy meeting in Houston includes CellChorus presentations on EV secretion and TIMING™ for manufacturing

PRESENTATION ALERT

HOUSTON, Texas — August 29, 2023 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, announced today that two members of the CellChorus team will present at the International Society for Cell & Gene Therapy (ISCT) North America Regional Meeting in Houston, Texas.

Process development:

Rebecca Berdeaux, PhD, VP of Science at CellChorus, will present "Functional single-cell analysis using TIMING™ accelerates CAR T cell process development by automated multi-parameter analysis of CAR T cell efficacy" at 9:15 AM CDT on Friday, September 8th. Co-authors include investigators from Indee Labs and USCF. The session will be led by Jason Bock, PhD, from CTMC (a partnership between MD Anderson and National Resilience). Additional talks in the session will be presented by representatives from the Mayo Clinic, Children's National Hospital, Fred Hutchinson Cancer Center, and GenCure. Dr. Berdeaux will also present a poster 6:30-8:00 PM CDT on Friday, September 8th.

Extracellular vesicles:

Mohsen Fathi, PhD, Head of Technology at CellChorus, will present "Single-cell EV profiling with TIMING™ identifies a gene signature associated with metastatic breast cancer" at 4:30 PM CDT on Saturday, September 9th. Co-authors include investigators from the University of Houston and MD Anderson. The session will be led by Jaap Jan Boelens, MD, PhD, from Memorial Sloan Kettering. Additional talks in the session will be presented by representatives from bioMérieux, Memorial Sloan Kettering, Baylor College of Medicine, Texas A&M, and Curate Biosciences. Dr. Fathi will also present a poster 5:30-7:00 PM CDT on Saturday, September 9th.

The complete program is now available on the ISCT North America meeting website:

About CellChorus

CellChorus is the leader in applying artificial intelligence (AI) to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids™ (TIMING™) with neural network-based AI to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.